Theriva Biologics, Inc. TOVX

Annual Quarterly

No annual revenue total was found in Theriva Biologics, Inc.'s SEC filings.

Theriva Biologics, Inc. (TOVX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.7 million. As of Jun 30, 2026 it held $11.3 million in cash and investments and $1.9 million in total debt.

Revenue
—
Net income (TTM)
$-11.62M
+60.7% vs year-ago TTM
Operating cash flow (TTM)
$-12.74M
+29.5% vs year-ago TTM
Free cash flow (TTM)
$-12.76M
+29.4% vs year-ago TTM
EPS (TTM)
$-0.42
+95.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
45.89M
+1549.4% vs prior year
Net cash
$9.44M
as of Jun 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TOVX (NYSE)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Rockville, MD
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
894158
Former names
Synthetic Biologics, Inc. (until Oct 12, 2022); ADEONA PHARMACEUTICALS, INC. (until Feb 17, 2012); PIPEX PHARMACEUTICALS, INC. (until Oct 16, 2008); SHEFFIELD PHARMACEUTICALS INC (until Dec 8, 2006); SHEFFIELD MEDICAL TECHNOLOGIES INC (until May 14, 1997)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Operating income
-$24.1M
-$26.3M
-$21.4M
-$21.6M
-$14.3M
Net income
-$23.7M
-$25.7M
-$18.3M
-$19.7M
-$14.3M
Diluted EPS
-$2.08
-$19.03
-$28.48
-$1.31
-$1.90
Operating cash flow
-$16.7M
-$16.9M
-$19.0M
-$19.1M
-$12.9M
Free cash flow
-$16.7M
-$16.9M
-$19.2M
-$19.2M
-$12.9M
Total assets
$38.2M
$35.4M
$55.2M
$71.9M
$70.4M
Total liabilities
$22.9M
$16.3M
$15.5M
$17.3M
$5.0M
Stockholders' equity
$15.4M
$19.1M
$37.0M
$51.8M
$65.4M
Cash and investments
$13.1M
$11.6M
$23.2M
$41.8M
$67.3M
Total debt
$2.6M
$1.5M
$2.2M
$1.7M
$1.5M

Recent SEC filings

Form Description Filed Period
8-K Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
 Nov 2, 2026 Oct 30, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026
8-K Current report
Regulation FD disclosure, Other events
 Aug 6, 2026 Aug 6, 2026
8-K Current report
Officer or director change, Shareholder vote results
 Aug 4, 2026 Aug 3, 2026
8-K Current report
Regulation FD disclosure, Other events
 Jul 7, 2026 Jul 7, 2026

All 1000 Theriva Biologics, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.